| Trial ID: | L0491 |
| Source ID: | NCT06344936
|
| Associated Drug: |
Hrs-1780 Tablets; Itraconazole Capsules; Rifampicin Capsules
|
| Title: |
Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects
|
| Acronym: |
|
| Status: |
NOT_YET_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease(CKD)
|
| Interventions: |
DRUG: HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules
|
| Outcome Measures: |
Primary: Assess the Cmax of HRS-1780 in plasma., About 3 days after the dose.|Assess the Tmax of HRS-1780 in plasma., About 3 days after the dose.|Assess the t1/2 of HRS-1780 in plasma., About 3 days after the dose.|Assess the AUC0-t of HRS-1780 in plasma., About 3 days after the dose.|Assess the AUC0-inf of HRS-1780 in plasma., About 3 days after the dose. | Secondary: Assess the incidence and severity of adverse events in healthy subjects after administration of HRS-1780 tablets., About a month from the first medication.
|
| Sponsor/Collaborators: |
Sponsor: Shandong Suncadia Medicine Co., Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
28
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2024-04
|
| Completion Date: |
2024-07
|
| Results First Posted: |
|
| Last Update Posted: |
2024-04-03
|
| Locations: |
Beijing Hospital, Beijing, Beijing, 100730, China
|
| URL: |
https://clinicaltrials.gov/show/NCT06344936
|
